Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 antibody-deactivated autologous T-cell therapy for recurrent platinum-resistant or refractory ovarian cancer
ChiCTR2000039213Phase 2Recruiting
- Sponsor
- The Third Affiliated Hospital of Chongqing Medical University
- Start
- Nov 2020
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-1 antibody-deactivated autologous T lymphoid cells in ovarian cancer, sponsored by The Third Affiliated Hospital of Chongqing Medical University. Primary endpoints: Objective response rate, Duration of response and 1 more. Started Nov 2020; status: recruiting.
02
Drugs
PD-1 antibody-deactivated autologous T lymphoid cells
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2000039213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039213.